Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (NASDAQ: APYX) is a cutting-edge energy technology company that develops, manufactures, and markets advanced medical devices for the cosmetic and surgical markets globally. The company operates through two primary segments: Advanced Energy and Original Equipment Manufacturing (OEM).
Under the Renuvion brand, Apyx Medical offers proprietary helium plasma and radiofrequency technology, which is widely used in cosmetic surgery. This innovative technology provides surgeons with the ability to apply controlled heat to tissues, optimizing results in procedures such as body contouring and liposuction. The J-Plasma system, marketed for surgical applications within hospitals, minimizes unintended tissue trauma during surgical operations.
Recent achievements underline Apyx Medical's commitment to advancing medical technology. In the third quarter of 2023, the company reported a 31% year-over-year increase in total revenue, highlighted by a 39% increase in Advanced Energy sales. Significant strides were made in developing the Apyx One Generator and associated accessories, which have seen robust global demand.
From a financial perspective, Apyx Medical continues to strengthen its position. For the year ending December 31, 2023, the company secured a new five-year credit agreement with Perceptive Advisors, providing up to $45 million in capital. This new agreement enhances the company's financial flexibility and supports its growth strategy.
The company's OEM segment collaborates with other medical device manufacturers to design, develop, and produce electrosurgical generators and related accessories. This segment saw a 14% year-over-year growth in revenue during the first three quarters of 2023.
Apyx Medical remains focused on leveraging regulatory clearances and expanding its market reach. Noteworthy is its active participation in industry conferences, such as the American Academy of Cosmetic Surgery’s Annual Meeting, where it showcases its innovative products and clinical findings. The company continues to invest in research and development to enhance its product offerings, and is committed to maintaining rigorous safety and efficacy standards, supported by an extensive portfolio of clinical evidence.
In summary, Apyx Medical Corporation is at the forefront of medical energy technology, providing innovative solutions that elevate patient care in both cosmetic and surgical markets. With a robust financial outlook, strategic industry partnerships, and a continuous drive for product excellence, Apyx Medical is poised for sustained growth and market leadership.
Apyx Medical Corporation (NASDAQ:APYX) announced its preliminary revenue results for Q4 and full year 2021, revealing $16.3 to $16.8 million in Q4, a year-over-year growth of 42% to 46%.
Advanced Energy sales ranged from $14.7 to $15.0 million, indicating a 49% to 52% increase compared to last year. For the full year, total revenue reached $48.0 to $48.5 million, a growth of 73% to 75%. However, OEM revenue faced a slight decline.
CEO Charlie Goodwin highlighted strong adoption of their Renuvion® technology in the U.S., driving sales above expectations.
Apyx Medical Corporation (NASDAQ:APYX) reported strong Q3 2021 results, with total revenue reaching $11.8 million, a 70% increase year-over-year. Advanced Energy sales surged 88% to $10.3 million, driven by increased demand for Renuvion® products. Net loss attributable to stockholders was $4.2 million, slightly higher than $3.7 million in Q3 2020. Full year revenue guidance was raised to $44-45 million, reflecting a year-over-year growth of 59%-62%. As of September 30, 2021, the company held $30.9 million in cash and equivalents.
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in several upcoming investor conferences. Events include virtual 1x1 meetings at the Craig-Hallum Alpha Select Conference on November 16, a presentation at the Stifel 2021 Virtual Healthcare Conference on November 17 at 3:20 p.m. ET, and additional meetings at the Canaccord Genuity Forum on November 18. A fireside chat will be available on-demand at the Piper Sandler Conference starting November 22. Audio webcasts will be accessible on their investor relations website.
Apyx Medical Corporation (NASDAQ:APYX) will release its financial results for Q3 FY2021 on November 11, 2021, after market closure. The Company specializes in medical devices using its Helium Plasma Technology, marketed as Renuvion® and J-Plasma®. A conference call will be held at 5:00 p.m. ET the same day to discuss these results. The call can be accessed by phone or via a live webcast. A telephonic replay will be available post-call. Apyx aims to enhance surgical precision and minimize tissue trauma with its innovative technology.
Apyx Medical Corporation (NASDAQ:APYX), a leader in advanced energy technologies, will participate in the Colliers Securities 2021 Institutional Investor Conference on September 9th, 2021. The event will be held virtually with management engaging in one-on-one meetings. Apyx is recognized for its innovative Helium Plasma Technology, marketed as Renuvion® in cosmetic surgery and J-Plasma® in the surgical market. These technologies enable precise tissue heating for enhanced surgical outcomes. For more details, visit www.ApyxMedical.com.
Apyx Medical Corporation (NASDAQ:APYX) has appointed Wendy Levine to its Board of Directors, effective August 25, 2021. Ms. Levine brings over 25 years of experience in healthcare marketing and advertising, having held leadership roles across various global healthcare companies including Johnson & Johnson and Novartis. CEO Charlie Goodwin expressed confidence in Ms. Levine's ability to enhance consumer marketing strategies for Apyx's innovative Helium Plasma Technology, marketed as Renuvion® and J-Plasma® in their respective markets.
Apyx Medical Corporation (NASDAQ:APYX) reported Q2 2021 financial results, showing significant growth with total revenue of $11.2 million, up 161% year-over-year. Advanced Energy revenue reached $10.0 million, surging 248%. Despite a net loss of $4.0 million, an improvement from $4.7 million in Q2 2020, the adjusted EBITDA loss narrowed to $2.4 million. The company updated its 2021 revenue outlook, projecting total revenue of $40.6 million to $42.6 million, reflecting 46% to 54% growth year-over-year.
Apyx Medical Corporation (NASDAQ:APYX) is set to release its financial results for Q2 2021 on August 12th, prior to the market opening. A conference call will be held at 8:00 a.m. ET on the same day to discuss the results and answer questions. Interested parties can listen by calling the provided numbers or accessing the live webcast through the Company’s website. Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Technology, which offers innovative solutions in cosmetic and surgical markets.
Apyx Medical Corporation (NASDAQ:APYX) announced participation in the JMP Securities Life Sciences Conference on June 16-17, where management will engage in a fireside chat on June 16 at 10:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through the company’s investor relations website, with an archive available post-conference. Apyx Medical specializes in Helium Plasma Technology, marketed as Renuvion® and J-Plasma®, which offers innovative solutions for cosmetic and surgical markets.
Apyx Medical Corporation (NASDAQ:APYX) has submitted a 510(k) premarket notification to the FDA seeking a specific clinical indication for its Renuvion device in dermal resurfacing procedures. This submission follows the recent completion of a U.S. IDE clinical study and signifies a crucial milestone for the company in expanding its market potential. CEO Charlie Goodwin noted the team's efforts in achieving this progress and expressed optimism regarding the FDA's review process.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
What does Apyx Medical Corporation specialize in?
What are the key product lines of Apyx Medical?
What recent financial achievements has Apyx Medical reported?
What significant recent projects has Apyx Medical undertaken?
Who are the typical customers for Apyx Medical's Renuvion technology?
What recent strategic financial move has Apyx Medical made?
How does Apyx Medical contribute to the OEM market?
What role does research and development play at Apyx Medical?
Where can I find more information about Apyx Medical's products?
What industry events does Apyx Medical participate in?
